KEGG   PATHWAY: hsa05213Help
Entry
hsa05213                    Pathway                                

Name
Endometrial cancer - Homo sapiens (human)
Description
Endometrial cancer (EC) is the most common gynaecological malignancy and the fourth most common malignancy in women in the developed world after breast, colorectal and lung cancer. Two types of endometrial carcinoma are distinguished with respect to biology and clinical course. Type-I carcinoma is related to hyperestrogenism by association with endometrial hyperplasia, frequent expression of estrogen and progesterone receptors and younger age, whereas type-II carcinoma is unrelated to estrogen, associated with atrophic endometrium, frequent lack of estrogen and progesterone receptors and older age. The morphologic differences in these cancers are mirrored in their molecular genetic profile with type I showing defects in DNA-mismatch repair and mutations in PTEN, K-ras, and beta-catenin, and type II showing aneuploidy, p53 mutations, and her2/neu amplification.
Class
Human Diseases; Cancers
BRITE hierarchy
Pathway map
Endometrial cancer
hsa05213

All organismsOrtholog table
Disease
H00026  
Endometrial Cancer
H00876  
Mismatch repair deficiency
Organism
Homo sapiens (human) [GN:hsa]
Gene
1950  
EGF; epidermal growth factor [KO:K04357]
1956  
EGFR; epidermal growth factor receptor [KO:K04361] [EC:2.7.10.1]
5290  
PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha [KO:K00922] [EC:2.7.1.153]
5293  
PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta [KO:K00922] [EC:2.7.1.153]
5291  
PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta [KO:K00922] [EC:2.7.1.153]
5294  
PIK3CG; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma [KO:K00922] [EC:2.7.1.153]
5295  
PIK3R1; phosphoinositide-3-kinase regulatory subunit 1 [KO:K02649]
23533  
PIK3R5; phosphoinositide-3-kinase regulatory subunit 5 [KO:K02649]
5296  
PIK3R2; phosphoinositide-3-kinase regulatory subunit 2 [KO:K02649]
8503  
PIK3R3; phosphoinositide-3-kinase regulatory subunit 3 [KO:K02649]
5728  
PTEN; phosphatase and tensin homolog [KO:K01110] [EC:3.1.3.67 3.1.3.48 3.1.3.16]
5170  
PDPK1; 3-phosphoinositide dependent protein kinase 1 [KO:K06276] [EC:2.7.11.1]
3611  
ILK; integrin linked kinase [KO:K06272] [EC:2.7.11.1]
207  
AKT1; AKT serine/threonine kinase 1 [KO:K04456] [EC:2.7.11.1]
208  
AKT2; AKT serine/threonine kinase 2 [KO:K04456] [EC:2.7.11.1]
10000  
AKT3; AKT serine/threonine kinase 3 [KO:K04456] [EC:2.7.11.1]
842  
CASP9; caspase 9 [KO:K04399] [EC:3.4.22.62]
572  
BAD; BCL2 associated agonist of cell death [KO:K02158]
2309  
FOXO3; forkhead box O3 [KO:K09408]
2885  
GRB2; growth factor receptor bound protein 2 [KO:K04364]
6654  
SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 [KO:K03099]
6655  
SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 [KO:K03099]
3265  
HRAS; HRas proto-oncogene, GTPase [KO:K02833]
3845  
KRAS; KRAS proto-oncogene, GTPase [KO:K07827]
4893  
NRAS; neuroblastoma RAS viral oncogene homolog [KO:K07828]
369  
ARAF; A-Raf proto-oncogene, serine/threonine kinase [KO:K08845] [EC:2.7.11.1]
673  
BRAF; B-Raf proto-oncogene, serine/threonine kinase [KO:K04365] [EC:2.7.11.1]
5894  
RAF1; Raf-1 proto-oncogene, serine/threonine kinase [KO:K04366] [EC:2.7.11.1]
5604  
MAP2K1; mitogen-activated protein kinase kinase 1 [KO:K04368] [EC:2.7.12.2]
5605  
MAP2K2; mitogen-activated protein kinase kinase 2 [KO:K04369] [EC:2.7.12.2]
5594  
MAPK1; mitogen-activated protein kinase 1 [KO:K04371] [EC:2.7.11.24]
5595  
MAPK3; mitogen-activated protein kinase 3 [KO:K04371] [EC:2.7.11.24]
2002  
ELK1; ELK1, ETS transcription factor [KO:K04375]
4292  
MLH1; mutL homolog 1 [KO:K08734]
999  
CDH1; cadherin 1 [KO:K05689]
1499  
CTNNB1; catenin beta 1 [KO:K02105]
29119  
CTNNA3; catenin alpha 3 [KO:K05691]
1495  
CTNNA1; catenin alpha 1 [KO:K05691]
1496  
CTNNA2; catenin alpha 2 [KO:K05691]
8312  
AXIN1; axin 1 [KO:K02157]
8313  
AXIN2; axin 2 [KO:K04385]
324  
APC; APC, WNT signaling pathway regulator [KO:K02085]
10297  
APC2; APC2, WNT signaling pathway regulator [KO:K02085]
2932  
GSK3B; glycogen synthase kinase 3 beta [KO:K03083] [EC:2.7.11.26]
6932  
TCF7; transcription factor 7 (T-cell specific, HMG-box) [KO:K02620]
83439  
TCF7L1; transcription factor 7 like 1 [KO:K04490]
6934  
TCF7L2; transcription factor 7 like 2 [KO:K04491]
51176  
LEF1; lymphoid enhancer binding factor 1 [KO:K04492]
4609  
MYC; v-myc avian myelocytomatosis viral oncogene homolog [KO:K04377]
595  
CCND1; cyclin D1 [KO:K04503]
7157  
TP53; tumor protein p53 [KO:K04451]
2064  
ERBB2; erb-b2 receptor tyrosine kinase 2 [KO:K05083] [EC:2.7.10.1]
Compound
C05981  
Phosphatidylinositol-3,4,5-trisphosphate
Reference
  Authors
Ryan AJ, Susil B, Jobling TW, Oehler MK.
  Title
Endometrial cancer.
  Journal
Cell Tissue Res 322:53-61 (2005)
Reference
  Authors
Lax SF.
  Title
Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification.
  Journal
Virchows Arch 444:213-23 (2004)
Reference
  Authors
Shiozawa T, Konishi I.
  Title
Early endometrial carcinoma: clinicopathology, hormonal aspects, molecular genetics, diagnosis, and treatment.
  Journal
Int J Clin Oncol 11:13-21 (2006)
Reference
  Authors
Hecht JL, Mutter GL.
  Title
Molecular and pathologic aspects of endometrial carcinogenesis.
  Journal
J Clin Oncol 24:4783-91 (2006)
Reference
  Authors
Matias-Guiu X, Catasus L, Bussaglia E, Lagarda H, Garcia A, Pons C, Munoz J, Arguelles R, Machin P, Prat J.
  Title
Molecular pathology of endometrial hyperplasia and carcinoma.
  Journal
Hum Pathol 32:569-77 (2001)
Reference
  Authors
Slomovitz BM, Broaddus RR, Burke TW, Sneige N, Soliman PT, Wu W, Sun CC, Munsell MF, Gershenson DM, Lu KH.
  Title
Her-2/neu overexpression and amplification in uterine papillary serous carcinoma.
  Journal
J Clin Oncol 22:3126-32 (2004)
Reference
PMID:7585656
  Authors
Saffari B, Jones LA, el-Naggar A, Felix JC, George J, Press MF.
  Title
Amplification and overexpression of HER-2/neu (c-erbB2) in endometrial cancers: correlation with overall survival.
  Journal
Cancer Res 55:5693-8 (1995)
Reference
  Authors
Kim D, Chung J.
  Title
Akt: versatile mediator of cell survival and beyond.
  Journal
J Biochem Mol Biol 35:106-15 (2002)
KO pathway
 

DBGET integrated database retrieval system